IL1F9 Protein (AA 13-164)

Catalog No. ABIN2666737

This Recombinant IL1F9 protein is produced in Escherichia coli (E. coli).

Quick Overview for IL1F9 Protein (AA 13-164) (ABIN2666737)

Target: IL1F9 (Interleukin 1 Family Member 9 (IL1F9))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 13-164

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: The ED50 is 1 - 5 ng/ml, corresponding to a specific activity of 0.2 - 1.0 x 106 units/mg, as determined by a dose-dependent stimulation of IL-6 secretion in 3T3L1 preadipocytes.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA.

Buffer: 0.22 μm filtered protein solution is in 20 mM MOPS, pH 7.4, 150 mM NaCl, 10 mM TCEP.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one week, at -20°C for three months, or at -70°C for 6 months.

Target Details

Target: IL1F9 (Interleukin 1 Family Member 9 (IL1F9))

Alternative Name: IL-36 gamma

Background: The IL-1 family is a group of cytokines comprised of 11 members, including the recently renamed IL-36 cytokines, IL-36α, β, and γ (previously known as IL-1F6, IL-1F8, and IL-1F9, respectively). IL-36γ signals through the IL-1 receptor family members IL-1Rrp2 and IL-1RAcP and can activate downstream MAP kinases and transcription factor NF-κB. IL-36γ is synthesized without signal peptide and the secretion pathway is unclear. It has been shown that like other IL-36 cytokines, the N-terminal processing of IL-36γ can significantly increase its biological activity. The possible processing enzymes are currently unknown. IL-36γ plays a significant role in the immune response, as low levels of IL-36 receptor IL-1Rrp can be detected on bone marrow-derived dendritic cells and CD4+ T cells. IL-36γ treatment can upregulate CD80, CD86 and MHC Class II, and proinflammatory cytokine production in dendritic cells. IL-36γ has also been implicated in airway hyperesponsiveness. Intranasal administration of recombinant IL-36γ in mice leads to epithelial cell hypertrophy, cellular infiltration, and mucus production. IL-36γ expression in the lungs of mice can be upregulated by allergic inflammation. In the skin, IL-36γ is primarily expressed by keratinocytes and its expression can be upregulated by inflammatory cytokines, toll-like receptor ligands, and some pathological conditions. IL-36γ is highly induced in psoriasis plaques.

Molecular Weight: The 152 amino acid recombinant protein has a predicted molecular mass of approximately 20 kDa. The DTT-reduced and non-reduced protein migrates at approximately 20 kDa by SDS-PAGE. The predicted N-terminal amino acid is Gly.